|
|
 |
| |
|
Home > Drug Companies > Amarin Pharmaceuticals
Amarin Pharmaceuticals
Amarin is a neuroscience company focused on the research, development and commercialisation of novel drugs for the treatment of central nervous system disorders. Amarin's leading pipeline product, MiraxionTM, is in phase III development for Huntington's disease and in phase II development for depression. Miraxion has been granted fast track designation by the U.S. Food and Drug Administration for HD and has received orphan drug status in the U.S and Europe. Amarin is listed on the Nasdaq small cap market has headquarters in London and a research and development facility in Stirling, Scotland.
A drug manufacturer is a business entity engaged in making, assembling, processing or modifying devices, or mixing, producing or preparing drugs in dosage forms by encapsulating, enitableting or other process, or packaging, repackaging or otherwise changing the container, wrapper or label of any package containing a drug or device in furtherance of the distribution of the drug or device from the original place of manufacture to the person who makes final delivery or sale to the ultimate consumer.
Amarin is using a novel, proprietary technology platform based on an understanding of the chemical nature of the brain. Unlike most organs, the brain is 60percent fat phospholipid and only 30percent protein. Just as oil and water do not mix, most drugs which easily dissolve in water do not readily penetrate the brain. Amarin's lipophilic drugs are predominantly fat-soluble and easily cross the blood brain barrier.
Miraxion for HD has been partnered in the major EU markets. Additionally, Amarin has licensed its intellectual property to a partner for the Japanese market for the treatment of CNS disorders. Amarin's goal is to capitalize on its strong reputation in neuroscience and to become a leader in the development and commercialization of novel drugs which address unmet medical needs. Amarin will develop its late-stage development pipeline initially focusing on HD and depression.
Back to Drug Companies
|
|
|
|
|
|
|
|